Blackstone Inc’s Teva Pharmaceuticals TEVA Stock Holding History

Blackstone Inc’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-137,056	Closed	-$4.28M	–	481
2025 Q4	$4.28M	Buy	137,056 +68,834	+101%	+$1.7M	0.02%	127
2025 Q3	$1.38M	Buy	+68,222	New	+$1.2M	0.01%	159

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackstone Inc's TEVA Position: Q1 2026 in Review

Blackstone Inc sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 137,056 shares — an estimated $4.28M sold.

Blackstone Inc first reported a position in TEVA in Q3 2025 and held it in 2 quarters. The position peaked at $4.28M in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Blackstone Inc reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Blackstone Inc sold 137,056 Teva Pharmaceuticals shares in Q1 2026, an estimated $4.28M.
Blackstone Inc first reported a position in Teva Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Blackstone Inc's Teva Pharmaceuticals position peaked at $4.28M in Q4 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.